Asset
EDP-305
Enanta Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03783897 | phase1 | completed | 2018-11-27 | 2019-06-04 | Enanta Pharmaceuticals, Inc | A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects |
| NCT04378010 | phase2 | terminated | 2020-01-27 | 2021-10-04 | Enanta Pharmaceuticals, Inc | A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH |
| NCT02918929 | phase1 | completed | 2016-09-01 | 2017-06-01 | Enanta Pharmaceuticals, Inc | A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD |
| NCT03207425 | phase1 | completed | 2017-06-14 | 2017-09-16 | Enanta Pharmaceuticals, Inc | A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers |
| NCT03394924 | phase2 | completed | 2017-12-27 | 2019-12-19 | Enanta Pharmaceuticals, Inc | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis |
FDA applications (0)
This company has no applications containing this asset.